https://www.selleckchem.com/pr....oducts/gsk3368715.ht
A conditional logistic regression model was used to estimate the rate ratio of PD according to β2-agonist use, rigorously controlling for confounding variables. RESULTS Among 242,218 COPD patients, 732 PD cases and 3,660 controls were identified. Use of β2 -agonists did not significantly affect the subsequent risk of PD (versus no use, adjusted rate ratios regular use, 1.14 [95% CI 0.93, 1.40, p=0.21], irregular use, 1.15 [95% CI 0.92, 1.45, p=0.22]). Results remained consistent with competing risk sensitivity analysis. CONCLUSION Us
Me gusta
Comentario
Compartir
